Naproxen + Pregabalin for Acute Pain

MB
Overseen ByMiroslav Backonja, M.D.
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: National Center for Complementary and Integrative Health (NCCIH)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain.

The study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen).

Up to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit.

The study includes several experimental pain tests. These include:

a heat and capsaicin skin test that causes short-term skin sensitivity,

a UVB light test that causes a temporary sunburn-like sensitivity, and

a cold pressor test, in which a hand is placed in very cold water for a short time.

Participants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done.

Each treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks.

This study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....

Who Is on the Research Team?

MB

Miroslav Backonja, M.D.

Principal Investigator

National Center for Complementary and Integrative Health (NCCIH)

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 years old or older.
* Have a skin type score between 2 and 5 (inclusive) on the Fitzpatrick Scale.
I reported a pain level between 4 and 9 during the screening test.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive pregabalin, naproxen, and placebo in a randomized order during three treatment periods, with a washout period of at least 48 hours between treatments.

Up to 10 weeks
Multiple visits for each treatment period

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Naproxen
  • Pregabalin

How Is the Trial Designed?

6

Treatment groups

Experimental Treatment

Group I: Sequence CBA (Placebo - Naproxen - Pregabalin)Experimental Treatment3 Interventions
Group II: Sequence CAB (Placebo - Pregabalin - Naproxen)Experimental Treatment3 Interventions
Group III: Sequence BCA (Naproxen - Placebo - Pregabalin)Experimental Treatment3 Interventions
Group IV: Sequence BAC (Naproxen - Pregabalin - Placebo)Experimental Treatment3 Interventions
Group V: Sequence ACB (Pregabalin - Placebo - Naproxen)Experimental Treatment3 Interventions
Group VI: Sequence ABC (Pregabalin - Naproxen - Placebo)Experimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Center for Complementary and Integrative Health (NCCIH)

Lead Sponsor

Trials
886
Recruited
677,000+